{"id":5317,"date":"2023-09-12T14:39:30","date_gmt":"2023-09-12T14:39:30","guid":{"rendered":"https:\/\/www.angelssante.fr\/?p=5317"},"modified":"2024-06-04T15:09:49","modified_gmt":"2024-06-04T15:09:49","slug":"abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante","status":"publish","type":"post","link":"https:\/\/www.angelssante.fr\/en\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/","title":{"rendered":"ABCELY raises over \u20ac2.4m to accelerate the development of its innovative anti-cancer therapeutic approach (FR)"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5317\" class=\"elementor elementor-5317\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-eadd657 e-flex e-con-boxed e-con e-parent\" data-id=\"eadd657\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1fbdb5c elementor-widget elementor-widget-heading\" data-id=\"1fbdb5c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Abcely, a Nantes-based biotech developing a brand-new anti-cancer treatment, announces that it has raised over \u20ac2.4 million from Angels Sant\u00e9, Go Capital, ICO and several private investors.\n<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-cdde377 e-flex e-con-boxed e-con e-child\" data-id=\"cdde377\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bb11ab5 elementor-widget elementor-widget-text-editor\" data-id=\"bb11ab5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><em><strong>Ce tour d\u2019amor\u00e7age permettra de valider la production industrielle d\u2019une nouvelle classe de mol\u00e9cules th\u00e9rapeutiques et d\u2019en poursuivre son d\u00e9veloppement pr\u00e9clinique en immuno-oncologie.<\/strong><\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-399b7fb elementor-widget elementor-widget-text-editor\" data-id=\"399b7fb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Laur\u00e9ate du concours i-Lab 2023, ABCELY est une start-up de biotechnologie de la sant\u00e9 sp\u00e9cialis\u00e9e dans le d\u00e9veloppement des Immunoglobulines de classe A (IgA). Le candidat m\u00e9dicament d\u00e9velopp\u00e9 par ABCELY, le ABC-101, est le premier anticorps monoclonal de classe A dirig\u00e9 contre un marqueur tumoral extr\u00eamement bien valid\u00e9 en oncologie, le CEA (Antig\u00e8ne Carcino-Embryonnaire) surexprim\u00e9 dans de nombreux cancers digestifs et muqueux (poumons, tractus uro-g\u00e9nital et glandulaires associ\u00e9s).<\/p><p>Le produit ABC-101 a \u00e9t\u00e9 g\u00e9n\u00e9r\u00e9 par la technologie HAMIGA\u2122 d\u00e9velopp\u00e9e par l\u2019unit\u00e9 de recherche CRIBL CNRS 7276\/INSERM\/Universit\u00e9 de Limoges. L\u2019administration orale de la forme humanis\u00e9e de ABC-101 dans un mod\u00e8le de souris transg\u00e9nique porteur d\u2019une greffe d\u2019ad\u00e9no-carcinome colorectal humain a montr\u00e9 une r\u00e9duction tr\u00e8s significative de la masse tumorale et constitue la premi\u00e8re d\u00e9monstration d\u2019une activit\u00e9 d\u2019une immunoglobuline par voie orale en canc\u00e9rologie.<\/p><p>R\u00e9pondant \u00e0 des \u00ab unmet needs \u00bb tr\u00e8s importants dans le traitement du cancer, des muqueuses en particulier, le candidat ABC-101 sera propos\u00e9 dans le cadre d\u2019un traitement des cancers de l\u2019\u0153sophage, de l\u2019estomac, du pancr\u00e9as ou du colon. En parall\u00e8le, ABCELY travaille \u00e0 l\u2019identification d\u2019un nouveau produit de classe IgA, pour une application dans les domaines particuli\u00e8rement adapt\u00e9s \u00e0 un \u00ab ciblage \u00bb des muqueuses tels que l\u2019oncologie, l\u2019immunologie ou l\u2019inflammation. ABCELY souhaite \u00e9galement d\u00e9velopper d&rsquo;autres approches th\u00e9rapeutiques proches de l&rsquo;ABC-101, pour le traitement de l&rsquo;endom\u00e9triose notamment. La start-up d\u00e9veloppera successivement chaque m\u00e9dicament jusqu\u2019au stade de la preuve de concept clinique (phase Ib\/IIa) avant cession \u00e0 un ou plusieurs groupes pharmaceutiques pour mise sur le march\u00e9 des produits.<\/p><p><b>Jean-Marc Herbert<\/b>, Pr\u00e9sident-fondateur de Abcely d\u00e9clare\u00a0: \u00ab\u00a0<em>Je suis heureux de porter avec Armelle Cuvillier, co-inventrice du ABC-101 et Olivier Favre-Bulle un projet bio-pharmaceutique sans \u00e9quivalent dans le domaine de l\u2019immuno-oncologie appliqu\u00e9 aux traitements des cancers des muqueuses, domaine th\u00e9rapeutique immense dont les besoins m\u00e9dicaux non satisfaits sont consid\u00e9rables<\/em>\u00a0\u00bb<\/p><p><b>Stephane Loze<\/b>, Responsable partenariats Angels Sant\u00e9, conclut pour sa part :\u00a0\u00ab\u00a0<em>Pour Angels Sant\u00e9 et ses Business Angels\u00a0passionn\u00e9s par l\u2018oncologie, les mots cl\u00e9s \u00e9taient bien r\u00e9unis pour se lancer dans l\u2019aventure ABCELY et participer au 1er financement de cet anti-cancereux innovant :\u00a0Immunoth\u00e9rapie, innovation disruptive via les IgA et une forme orale pour les cancers des muqueuses et surtout une \u00e9quipe exp\u00e9riment\u00e9e , accompagn\u00e9e par un fonds d\u00e8s le seed ! Nous sommes heureux et fiers de pouvoir participer activement \u00e0 cette aventure entrepreneuriale !<\/em>\u00a0\u00bb<\/p><p><strong>A propos d\u2019ABCELY<\/strong><\/p><p>ABCELY est une start-up de biotechnologie de la sant\u00e9 sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019une toute nouvelle classe de mol\u00e9cules th\u00e9rapeutiques, les Immunoglobulines de classe A. Elle a \u00e9t\u00e9 fond\u00e9e en mai 2022 \u00e0 Nantes en Loire-Atlantique par Jean-Marc Herbert, son CEO actuel, sur la base d&rsquo;une cession de license exclusive. Elle a pour mission essentielle de d\u00e9velopper des candidats m\u00e9dicament de nature biologique, tr\u00e8s sp\u00e9cifiquement des immunoglobulines de classe A, jusqu\u2019au stade de la preuve de concept clinique dans tous les domaines adressant des pathologies des muqueuses.<\/p><p><strong>A propos d\u2019Angels Sant\u00e9<\/strong><\/p><p>Angels Sant\u00e9 est le premier r\u00e9seau de Business Angels en Europe d\u00e9di\u00e9 \u00e0 la sant\u00e9 humaine et animale. Depuis sa cr\u00e9ation en 2008, elle accompagne des startups innovantes en biotech, medtech et sant\u00e9 num\u00e9rique. Sa force r\u00e9side dans son r\u00e9seau d&rsquo;investisseurs experts en sant\u00e9 ayant les connaissances n\u00e9cessaires pour fournir de la smart money \u00e0 des startups soigneusement s\u00e9lectionn\u00e9es, en leur apportant capitaux et expertise afin de soutenir leur lancement et leur d\u00e9veloppement.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ab3f92e e-flex e-con-boxed e-con e-parent\" data-id=\"ab3f92e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8c3b196 e-flex e-con-boxed e-con e-parent\" data-id=\"8c3b196\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Abcely, biotech Nantaise qui d\u00e9veloppe un tout nouveau traitement anti-cancer, annonce avoir lev\u00e9 plus de 2,4M\u20ac aupr\u00e8s notamment d&rsquo;Angels Sant\u00e9, Go Capital, de l&rsquo;ICO et de plusieurs investisseurs priv\u00e9s.<\/p>","protected":false},"author":2,"featured_media":6014,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6],"tags":[],"class_list":["post-5317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-du-cote-de-nos-start-ups"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante - Angels Sante<\/title>\n<meta name=\"description\" content=\"Abcely, biotech Nantaise qui d\u00e9veloppe un tout nouveau traitement anti-cancer, annonce avoir lev\u00e9 plus de 2,4M\u20ac aupr\u00e8s notamment d&#039;Angels Sant\u00e9, Go Capital, de l&#039;ICO et de plusieurs investisseurs priv\u00e9s.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.angelssante.fr\/en\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante - Angels Sante\" \/>\n<meta property=\"og:description\" content=\"Abcely, biotech Nantaise qui d\u00e9veloppe un tout nouveau traitement anti-cancer, annonce avoir lev\u00e9 plus de 2,4M\u20ac aupr\u00e8s notamment d&#039;Angels Sant\u00e9, Go Capital, de l&#039;ICO et de plusieurs investisseurs priv\u00e9s.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.angelssante.fr\/en\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/\" \/>\n<meta property=\"og:site_name\" content=\"Angels Sante\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.linkedin.com\/company\/angelssante\/?viewAsMember=true\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-12T14:39:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-04T15:09:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2023\/09\/6.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"755\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/\"},\"author\":{\"name\":\"caroline\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#\\\/schema\\\/person\\\/a3091af4aa360ddf6b6f0f176518b26e\"},\"headline\":\"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante\",\"datePublished\":\"2023-09-12T14:39:30+00:00\",\"dateModified\":\"2024-06-04T15:09:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/\"},\"wordCount\":715,\"publisher\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.angelssante.fr\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/6.png\",\"articleSection\":[\"Du c\u00f4t\u00e9 de nos start-ups\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/\",\"url\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/\",\"name\":\"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante - Angels Sante\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.angelssante.fr\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/6.png\",\"datePublished\":\"2023-09-12T14:39:30+00:00\",\"dateModified\":\"2024-06-04T15:09:49+00:00\",\"description\":\"Abcely, biotech Nantaise qui d\u00e9veloppe un tout nouveau traitement anti-cancer, annonce avoir lev\u00e9 plus de 2,4M\u20ac aupr\u00e8s notamment d'Angels Sant\u00e9, Go Capital, de l'ICO et de plusieurs investisseurs priv\u00e9s.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.angelssante.fr\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/6.png\",\"contentUrl\":\"https:\\\/\\\/www.angelssante.fr\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/6.png\",\"width\":2000,\"height\":755},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.angelssante.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.angelssante.fr\\\/\",\"name\":\"Angel Sante\",\"description\":\"Premier r\u00e9seau de Business Angels en Europe d\u00e9di\u00e9 \u00e0 la sant\u00e9.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.angelssante.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#organization\",\"name\":\"Angel Sante\",\"url\":\"https:\\\/\\\/www.angelssante.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.angelssante.fr\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/logo4-pdf.jpg\",\"contentUrl\":\"https:\\\/\\\/www.angelssante.fr\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/logo4-pdf.jpg\",\"width\":685,\"height\":290,\"caption\":\"Angel Sante\"},\"image\":{\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/angelssante\\\/?viewAsMember=true\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.angelssante.fr\\\/#\\\/schema\\\/person\\\/a3091af4aa360ddf6b6f0f176518b26e\",\"name\":\"caroline\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99fada4791cc438694b17db6c935e6be622048c73401455708bb9858b4a4cd29?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99fada4791cc438694b17db6c935e6be622048c73401455708bb9858b4a4cd29?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99fada4791cc438694b17db6c935e6be622048c73401455708bb9858b4a4cd29?s=96&d=mm&r=g\",\"caption\":\"caroline\"},\"url\":\"https:\\\/\\\/www.angelssante.fr\\\/en\\\/author\\\/caroline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante - Angels Sante","description":"Abcely, a Nantes-based biotech developing a brand-new anti-cancer treatment, announces that it has raised over \u20ac2.4 million from Angels Sant\u00e9, Go Capital, ICO and several private investors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.angelssante.fr\/en\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/","og_locale":"en_US","og_type":"article","og_title":"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante - Angels Sante","og_description":"Abcely, biotech Nantaise qui d\u00e9veloppe un tout nouveau traitement anti-cancer, annonce avoir lev\u00e9 plus de 2,4M\u20ac aupr\u00e8s notamment d'Angels Sant\u00e9, Go Capital, de l'ICO et de plusieurs investisseurs priv\u00e9s.","og_url":"https:\/\/www.angelssante.fr\/en\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/","og_site_name":"Angels Sante","article_publisher":"https:\/\/www.linkedin.com\/company\/angelssante\/?viewAsMember=true","article_published_time":"2023-09-12T14:39:30+00:00","article_modified_time":"2024-06-04T15:09:49+00:00","og_image":[{"width":2000,"height":755,"url":"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2023\/09\/6.png","type":"image\/png"}],"author":"caroline","twitter_card":"summary_large_image","twitter_misc":{"Written by":"caroline","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/#article","isPartOf":{"@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/"},"author":{"name":"caroline","@id":"https:\/\/www.angelssante.fr\/#\/schema\/person\/a3091af4aa360ddf6b6f0f176518b26e"},"headline":"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante","datePublished":"2023-09-12T14:39:30+00:00","dateModified":"2024-06-04T15:09:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/"},"wordCount":715,"publisher":{"@id":"https:\/\/www.angelssante.fr\/#organization"},"image":{"@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/#primaryimage"},"thumbnailUrl":"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2023\/09\/6.png","articleSection":["Du c\u00f4t\u00e9 de nos start-ups"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/","url":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/","name":"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante - Angels Sante","isPartOf":{"@id":"https:\/\/www.angelssante.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/#primaryimage"},"image":{"@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/#primaryimage"},"thumbnailUrl":"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2023\/09\/6.png","datePublished":"2023-09-12T14:39:30+00:00","dateModified":"2024-06-04T15:09:49+00:00","description":"Abcely, a Nantes-based biotech developing a brand-new anti-cancer treatment, announces that it has raised over \u20ac2.4 million from Angels Sant\u00e9, Go Capital, ICO and several private investors.","breadcrumb":{"@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/#primaryimage","url":"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2023\/09\/6.png","contentUrl":"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2023\/09\/6.png","width":2000,"height":755},{"@type":"BreadcrumbList","@id":"https:\/\/www.angelssante.fr\/abcely-leve-plus-de-24-me-pour-accelerer-le-developpement-de-son-approche-therapeutique-anti-cancereuse-innovante\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.angelssante.fr\/"},{"@type":"ListItem","position":2,"name":"ABCELY l\u00e8ve plus de 2,4 M\u20ac pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son approche th\u00e9rapeutique anti-canc\u00e9reuse innovante"}]},{"@type":"WebSite","@id":"https:\/\/www.angelssante.fr\/#website","url":"https:\/\/www.angelssante.fr\/","name":"Angel Sante","description":"Premier r\u00e9seau de Business Angels en Europe d\u00e9di\u00e9 \u00e0 la sant\u00e9.","publisher":{"@id":"https:\/\/www.angelssante.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.angelssante.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.angelssante.fr\/#organization","name":"Angel Sante","url":"https:\/\/www.angelssante.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.angelssante.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2024\/02\/logo4-pdf.jpg","contentUrl":"https:\/\/www.angelssante.fr\/wp-content\/uploads\/2024\/02\/logo4-pdf.jpg","width":685,"height":290,"caption":"Angel Sante"},"image":{"@id":"https:\/\/www.angelssante.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/angelssante\/?viewAsMember=true"]},{"@type":"Person","@id":"https:\/\/www.angelssante.fr\/#\/schema\/person\/a3091af4aa360ddf6b6f0f176518b26e","name":"caroline","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/99fada4791cc438694b17db6c935e6be622048c73401455708bb9858b4a4cd29?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/99fada4791cc438694b17db6c935e6be622048c73401455708bb9858b4a4cd29?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/99fada4791cc438694b17db6c935e6be622048c73401455708bb9858b4a4cd29?s=96&d=mm&r=g","caption":"caroline"},"url":"https:\/\/www.angelssante.fr\/en\/author\/caroline\/"}]}},"_links":{"self":[{"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/posts\/5317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/comments?post=5317"}],"version-history":[{"count":6,"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/posts\/5317\/revisions"}],"predecessor-version":[{"id":5937,"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/posts\/5317\/revisions\/5937"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/media\/6014"}],"wp:attachment":[{"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/media?parent=5317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/categories?post=5317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.angelssante.fr\/en\/wp-json\/wp\/v2\/tags?post=5317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}